AU2001253886A1 - Methylxanthines in the diagnosis and treatment of autistic disorder - Google Patents

Methylxanthines in the diagnosis and treatment of autistic disorder

Info

Publication number
AU2001253886A1
AU2001253886A1 AU2001253886A AU5388601A AU2001253886A1 AU 2001253886 A1 AU2001253886 A1 AU 2001253886A1 AU 2001253886 A AU2001253886 A AU 2001253886A AU 5388601 A AU5388601 A AU 5388601A AU 2001253886 A1 AU2001253886 A1 AU 2001253886A1
Authority
AU
Australia
Prior art keywords
methylxanthines
diagnosis
treatment
autistic disorder
autistic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001253886A
Inventor
James R. Rusche
Jundong Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Repligen Corp
Original Assignee
Repligen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repligen Corp filed Critical Repligen Corp
Publication of AU2001253886A1 publication Critical patent/AU2001253886A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/14Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555Hetero-N
AU2001253886A 2000-04-12 2001-04-12 Methylxanthines in the diagnosis and treatment of autistic disorder Abandoned AU2001253886A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19642300P 2000-04-12 2000-04-12
US60196423 2000-04-12
PCT/US2001/040505 WO2001079837A1 (en) 2000-04-12 2001-04-12 Methylxanthines in the diagnosis and treatment of autistic disorder

Publications (1)

Publication Number Publication Date
AU2001253886A1 true AU2001253886A1 (en) 2001-10-30

Family

ID=22725358

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001253886A Abandoned AU2001253886A1 (en) 2000-04-12 2001-04-12 Methylxanthines in the diagnosis and treatment of autistic disorder

Country Status (3)

Country Link
US (1) US6365593B2 (en)
AU (1) AU2001253886A1 (en)
WO (1) WO2001079837A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7897141B2 (en) * 2002-04-01 2011-03-01 Drexel University Echogenic polymer microcapsules and nanocapsules and methods for production and use thereof
US7947285B2 (en) * 2003-12-12 2011-05-24 Fein Seymour H Methods for preventing post endoscopic retrograde cholangiopancreatography pancreatitis
US7381698B2 (en) * 2003-12-12 2008-06-03 Chirhoclin, Inc. Methods for treatment of acute pancreatitis
US10060932B2 (en) 2013-07-09 2018-08-28 Stemina Biomarker Discovery, Inc. Biomarkers of autism spectrum disorder
US9176113B1 (en) * 2014-04-11 2015-11-03 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
US20150294081A1 (en) 2014-04-11 2015-10-15 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
US10525020B2 (en) 2015-02-11 2020-01-07 Laboratory Corporation Of America Holdings Metabolic markers of attention deficit hyperactivity disorder
WO2017210540A1 (en) 2016-06-03 2017-12-07 The Trustees Of Columbia University In The City Of New York Methods of treating prader-willi syndrome

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61277618A (en) * 1985-06-04 1986-12-08 Suntory Ltd Remedy for autism
US5008251A (en) * 1986-03-27 1991-04-16 The Regents Of The University Of California Method of treating autism
FR2665636B1 (en) * 1990-08-10 1994-10-07 Adir USE OF A TRIMETHYL-1,3,7 XANTHINE DERIVATIVE FOR THE TREATMENT OF MEMORY DISORDERS, INTELLECTUAL DISORDERS OF SENESCENCE AND ALZHEIMER'S DISEASE.
FR2692784B1 (en) 1992-06-24 1995-06-30 Pf Medicament USE OF GUANOSINE, ITS PRECURSORS AND DERIVATIVES FOR THE MANUFACTURE OF MEDICINES FOR TREATING CEREBRAL FUNCTIONAL DEFICITS.
US5686311A (en) 1995-06-23 1997-11-11 The Children's Mercy Hospital Diagnosis of autism and treatment therefor
JP2002501616A (en) * 1997-05-19 2002-01-15 リプリゲン コーポレーション Methods to assist in differential diagnosis and treatment of autistic syndrome

Also Published As

Publication number Publication date
US20020019407A1 (en) 2002-02-14
US6365593B2 (en) 2002-04-02
WO2001079837A1 (en) 2001-10-25

Similar Documents

Publication Publication Date Title
AU2001293553A1 (en) Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment
AU2001236798A1 (en) Optically-active nanoparticles for use in therapeutic and diagnostic methods
HUP0203367A3 (en) Benzylidine-thiazolidinediones and analogues and their use in the treatment of diabetes
IL138732A0 (en) The use of polyamines in the treatment of dermatological symptoms
IL187512A0 (en) Use of (s,s)-reboxetine in the treatment of pain conditions and incontinence
IL205242A0 (en) Substituted oxazolidinones and their use in the field of blood coagulation
AU3021001A (en) Thiazolidine carboxylic acid derivatives and their use in the treatment of cancer
AU2002339128A1 (en) Use of reelin, gas6, and protein s in the treatment of neural disorders
AU2002308348A1 (en) Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
CA2387873A1 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
AU2001283285A1 (en) Antimicrobial composition and methods of use in the treatment of disease
AU2001270484A1 (en) Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations
AU2003286285A1 (en) Use of fgf-18 in the diagnosis and treatment of memory disorders
WO2003099841A9 (en) Peptides and the use thereof in darkening the skin
AU2001265186A1 (en) Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions
IL160018A0 (en) Isoxazolopyridinones and use thereof in the treatment of parkinson's disease
AU2001253886A1 (en) Methylxanthines in the diagnosis and treatment of autistic disorder
AU2002243363A1 (en) Use of aziridino-compounds in the treatment of immune dysfunctions
AU2002352566A1 (en) Use of corrinoids in the treatment of skin diseases
EP1322778A4 (en) Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
AU2002346049A1 (en) Coactivators in the diagnosis and treatment of breast cancer
AU2002232912A1 (en) Carbene porphyrins and carbene porphyrinoids for use in medical diagnosis and treatment
AU6653698A (en) Use of the p-ten suppressor gene in diagnosis and treatment of cancer
GB0008326D0 (en) Diagnosis and treatment of autism and related disorders
AU2001285026A1 (en) Methods and compositions for use in the diagnosis and treatment of chronic immune disease